Riskpilot← Back to searchSign inGet full accessMedilect AB
ABActiveOrg 5569401192Institutsvägen 5Other education n.e.c. · NACE 8559Est. 20131 employees
Revenue 2025
SEK 272K
-33% vs 2024
EBITDA margin
85.4%
-35% vs 2024
Equity ratio
95.7%
Financial strength
Net profit 2025
SEK 190K
-38% vs 2024
| Revenue | SEK 272K | -33% |
| EBITDA | SEK 233K | -35% |
| Net profit | SEK 190K | -38% |
| Total assets | SEK 1,4M | -2% |
| Equity | SEK 1,4M | -1% |
| Employees | 1 | — |
Legal name
Medilect AB
Org number
5569401192
Legal form
Aktiebolag
NACE code
8559 · Other education n.e.c.
Founded
23 augusti 2013
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget ska bedriva bemanningsverksamhet inom vårdsektorn, konsult- och utbildningsverksamhet inom läkemedelsområdet samt därmed förenlig verksamhet. Handel med aktier och värdepapper.
Address
Institutsvägen 5
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 219 | 242 | 612 | 405 | 272 |
| Staff expenses | — | — | — | — | −1 |
| EBITDA | 201 | 207 | 575 | 360 | 233 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 201 | 207 | 575 | 360 | 233 |
| Net financials | — | 0 | 15 | 22 | 6 |
| Profit before tax | 200 | 208 | 590 | 381 | 238 |
| Tax | −41 | −43 | −120 | −77 | −49 |
| Net profit | 159 | 165 | 469 | 304 | 190 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 112 | 1 097 | 1 444 | 1 472 | 1 435 |
| Equity | 1 046 | 1 021 | 1 300 | 1 394 | 1 374 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 66 | 76 | 144 | 78 | 62 |
| Total debt | 66 | 76 | 144 | 78 | 62 |
EBITDA margin
85.4%
This company
15.8%
Market median
+441% vs market
20212025
Equity ratio
95.7%
This company
38.2%
Market median
+151% vs market
20212025
Return on equity
13.8%
This company
18.4%
Market median
+25% vs market
20212025
Net profit margin
69.6%
This company
8.1%
Market median
+759% vs market
20212025
Asset turnover
0.19×
This company
1.12×
Market median
-83% vs market
20212025
Debt / equity
0.04×
This company
0.62×
Market median
+94% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JA Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Medilect AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jan Anders Själander | Chief Executive Officer | 0 companies |
| Maria Sara Christina Själander | Board of Directors | 0 companies |